Trapping all ERBB ligands decreases pancreatic lesions in a murine model of pancreatic ductal adenocarcinoma
K Hedegger, A Blutke, T Hommel, KE Auer… - Molecular …, 2023 - Wiley Online Library
Pancreatic ductal adenocarcinoma (PDAC) is among the deadliest of cancers. Attempts to
develop targeted therapies still need to be established. Some oncogenic mechanisms in …
develop targeted therapies still need to be established. Some oncogenic mechanisms in …
Oncogenic ERBB2 aberrations and KRAS mutations cooperate to promote pancreatic ductal adenocarcinoma progression
Z Li, C Shao, X Liu, X Lu, X Jia, X Zheng… - …, 2020 - academic.oup.com
Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease with few therapeutic
options, representing one of the great challenges in oncology. Activating KRAS mutation …
options, representing one of the great challenges in oncology. Activating KRAS mutation …
Dual targeting of ErbB-2/ErbB-3 results in enhanced antitumor activity in preclinical models of pancreatic cancer
R Ghasemi, IG Rapposelli, E Capone, C Rossi… - Oncogenesis, 2014 - nature.com
ErbB-3 and its ligand NRG-1β are key players in driving oncogenic signaling and resistance
to therapy through the activation of the PI3K/Akt pathway. We have recently reported that …
to therapy through the activation of the PI3K/Akt pathway. We have recently reported that …
Ligand stimulation of ErbB4 and a constitutively-active ErbB4 mutant result in different biological responses in human pancreatic tumor cell lines
CP Mill, KL Gettinger, DJ Riese II - Experimental cell research, 2011 - Elsevier
Pancreatic cancer is the fourth leading cause of cancer death in the United States. Indeed, it
has been estimated that 37,000 Americans will die from this disease in 2010. Late …
has been estimated that 37,000 Americans will die from this disease in 2010. Late …
Unraveling ERBB network dynamics upon betacellulin signaling in pancreatic ductal adenocarcinoma in mice
K Hedegger, H Algül, M Lesina, A Blutke… - Molecular …, 2020 - Wiley Online Library
Pancreatic ductal adenocarcinoma (PDAC) will soon belong to the top three cancer killers.
The only approved specific PDAC therapy targets the epidermal growth factor receptor …
The only approved specific PDAC therapy targets the epidermal growth factor receptor …
The ERBB receptor inhibitor dacomitinib suppresses proliferation and invasion of pancreatic ductal adenocarcinoma cells
Purpose Pancreatic ductal adenocarcinoma (PDAC), the most common malignancy of the
pancreas, is the fourth most common cause of cancer-related death in the USA. Local …
pancreas, is the fourth most common cause of cancer-related death in the USA. Local …
Differential impact of the ERBB receptors EGFR and ERBB2 on the initiation of precursor lesions of pancreatic ductal adenocarcinoma
Earlier diagnosis of pancreatic ductal adenocarcinoma (PDAC) requires better
understanding of the mechanisms driving tumorigenesis. In this context, depletion of …
understanding of the mechanisms driving tumorigenesis. In this context, depletion of …
Coordinate transcriptional regulation of ErbB2/3 by C-terminal binding protein 2 signals sensitivity to ErbB2 inhibition in pancreatic adenocarcinoma
KK Chougoni, H Park, PK Damle, T Mason, B Cheng… - Oncogenesis, 2023 - nature.com
There is a critical need to identify new therapeutic vulnerabilities in pancreatic ductal
adenocarcinoma (PDAC). Transcriptional co-regulators C-terminal binding proteins (CtBP) 1 …
adenocarcinoma (PDAC). Transcriptional co-regulators C-terminal binding proteins (CtBP) 1 …
ErbB3 expression promotes tumorigenesis in pancreatic adenocarcinoma
JS Liles, JP Arnoletti, CWD Tzeng… - Cancer biology & …, 2010 - Taylor & Francis
Historically, ErbB3 has been overlooked within the ErbB receptor family due to its perceived
lack of tyrosine kinase activity. We have previously demonstrated that in pancreatic cancer …
lack of tyrosine kinase activity. We have previously demonstrated that in pancreatic cancer …
Dual Inhibition of KRASG12D and Pan-ERBB Is Synergistic in Pancreatic Ductal Adenocarcinoma
Pancreatic ductal adenocarcinoma (PDAC) is a lethal cancer with a low survival rate.
Recently, new drugs that target KRASG12D, a common mutation in PDAC, have been …
Recently, new drugs that target KRASG12D, a common mutation in PDAC, have been …